PDF herunterladen
Exp Clin Endocrinol Diabetes 2023; 131(01/02): 61-65
DOI: 10.1055/a-1946-3783
German Diabetes Association: Clinical Practice Guidelines

Nephropathy in Diabetes

Ludwig Merker
1   Diabetologie im MVZ am Park Ville d’Eu, Haan, Germany
,
Thomas Ebert
2   Department of Endocrinology, Nephrology and Rheumatology, University Hospital Leipzig, Leipzig, Germany
,
Martina Guthoff
3   Department of Diabetology, Endocrinology, Nephrology, University Hospital Tübingen, Tübingen, Germany
,
Berend Isermann
4   Institute for Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints
Notice of update

The DDG practice recommendations are updated regularly during the second half of the calendar year. Please ensure that you read and cite the respective current version.

Updates To Content And Different Recommendations Compared To The Previous Year’s Version

Recommendation 1: Additional information added to the general measures

Reason: Important measures for the self-management of CKD

Supporting reference: [11]

Recommendation 2: Blood pressure target value lowered

Reason: Current guideline recommendation

Supporting reference: [12]

Recommendation 3: Use of non-steroidal mineralocorticoid receptor antagonists in future

Reason: New data from endpoint studies

Supporting reference: [13] [14]

Recommendation 4: Use of some SGLT-2 inhibitors also in stage G4

Reason: Newer data

Supporting reference: [11]



Publikationsverlauf

Artikel online veröffentlicht:
23. Januar 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mogensen CE. Introduction: Diabetes mellitus and the kidney. Kidney Int 1982; 21: 673-675
    CrossrefPubMedGoogle Scholar
  • 2 KDIGO KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150
    PubMedGoogle Scholar
  • 3 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104
    CrossrefPubMedGoogle Scholar
  • 4 Buse JB, Wexler DJ, Tsapas A. et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63: 221-228
    CrossrefPubMedGoogle Scholar
  • 5 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapie des Typ-2-Diabetes. Diabetologie 2019; 14: 167-187
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 6 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41: 111-188
    CrossrefPubMedGoogle Scholar
  • 7 Kristensen SL, Rørth R, Jhund PS. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7: 776-785
    CrossrefPubMedGoogle Scholar
  • 8 Zelniker TA, Wiviott SD, Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-39
    CrossrefPubMedGoogle Scholar
  • 9 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
    CrossrefPubMedGoogle Scholar
  • 10 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446
    CrossrefPubMedGoogle Scholar
  • 11 Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98: 1-115
    CrossrefPubMedGoogle Scholar
  • 12 Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99: 1-87
    CrossrefPubMedGoogle Scholar
  • 13 Bakris GL, Agarwal R, Anker SD. et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383: 2219-2229
    CrossrefPubMedGoogle Scholar
  • 14 Pitt B, Filippatos G, Agarwal R. et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385: 2252-2263
    CrossrefPubMedGoogle Scholar
  • 15 Bally L, Gubler P, Thabit H. et al. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int 2019; 96: 593-596
    CrossrefPubMedGoogle Scholar
  • 16 Boughton CK, Tripyla Q, Hartnell S. et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med 2021; 27 (8): 1471–1476. Erratum in: Nat Med 2021; 27: 1850
    PubMedGoogle Scholar